Maridebart cafraglutideMariTide
GLP-1 agonism paired with GIP receptor antagonism — the opposite GIP direction to tirzepatide.
Identity
- Class
- GLP-1 agonist–GIP-antagonist peptide–antibody conjugate
- Source
- Synthetic; anti-GIP-receptor antibody conjugated to GLP-1 peptides
- Receptor
- GLP-1 receptor (agonist) + GIP receptor (antagonist)
Mechanism
Maridebart cafraglutide pairs GLP-1 receptor agonism with GIP receptor antagonism on a single peptide–antibody conjugate — an anti-GIP-receptor antibody carrying GLP-1 peptides. It blocks the very GIP receptor that tirzepatide activates, yet also drives weight loss, and its antibody scaffold gives a long half-life that enables once-monthly dosing. It is investigational.
Reference notes
- Turns the GIP receptor off while turning GLP-1 on — the opposite GIP direction to tirzepatide, and both approaches reduce weight.
- Built as a peptide–antibody conjugate, whose long half-life supports once-monthly dosing.
- Investigational — phase 2 reported, larger trials ongoing.
Selected literature
Curated peer-reviewed reviews, sourced from PubMed. Selected for relevance, not exhaustive — open any entry on PubMed for the full record and its primary citations.
- 1.Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial · The New England journal of medicine, 2025 · PMID 40549887
- 2.A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings · Nature metabolism, 2024 · PMID 38316982